Navigation Links
Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Date:10/1/2007

NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference in New York City. Dr. Henderson's presentation will take place on Wednesday, October 3rd at 12:30 pm ET.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
7. The Past, Present and Future of HLA Typing
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... of the "US ACO IT Spending Outlook 2018" ... expected that number of lives covered by ACO would ... In this report, the ACO IT spending has been ... spending on software and spending on services. Our research ...
(Date:5/1/2015)... Calif. , May 1, 2015  Thoratec Corporation (NASDAQ: ... therapies to save, support and restore failing hearts, announced today ... newly created role of President, International. This new ... Thoratec commercial operations outside of North America ... , and Latin America , and ...
(Date:5/1/2015)... 2015  CytRx Corporation (CYTR), a biopharmaceutical research ... financial results for the three months ended March ... accomplishments and upcoming milestones for its clinical development ... the early months of 2015, including the announcement ... aldoxorubicin in patients with soft tissue sarcoma, and ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... SAN DIEGO, Dec. 12, 2011  Daiichi Sankyo Company, Limited ... pooled analysis showing that edoxaban, a direct oral once-daily ... venous thromboembolism (VTE) following total knee or hip arthroplasty, ... lower incidence of a composite of deep vein thrombosis ...
... Partnership (SRP) Inc. today announced the availability of ... Third Party Administrators (TPAs), brokers, and other users to ... software tools and the need for expensive outsourcing, SRP,s ... affordable licensing rates with no initial subscription fees. ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5SRP Announces Plan Doc Builder for TPAs and Brokers of Healthcare Plans 2
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured ... which features the latest and coolest technology products available ... reporter for NewsWatch, conducted the review and shared with ... , Music is an important part of people’s lives ... given the royal treatment. Peachtree Audio does just that ...
(Date:5/2/2015)... Kare Visits LLC. launched in Chicago in ... Kare Visits offers relief for caregivers by visiting loved ... According to the Caregiver Action Network, eight in ten ... hours a week caring for an elderly or disabled loved ... a nurse, a caregiver is now empowered to schedule an ...
(Date:5/2/2015)... Portland, OR (PRWEB) May 02, 2015 ... that it has submitted plans to offer its new ... Oregon Exchange. The ZOOM+ Personal Health Insurance System is ... ground up to enhance human performance. ZOOM+ Personal Health ... a healthcare delivery system that are subject to review ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... for self-destruction. Many cells die peacefully. Others cause ... cell death pathways simply and quietly remove unwanted cells, ... who study the mechanisms of cell destruction. , ... dangerous cell, such as a cell infected with Salmonella, ...
... with the syndrome were more exposed to particular compounds ... new scientific review finds a strong association between exposure ... by many veterans. , The class of chemicals, ... nerve agents and in pills given to soldiers to ...
... 10, 2008) -- When human umbilical cord blood ... researchers at the University of South Florida (USF) ... region of the animals brains and a subsequent ... online at BMC Neuroscience ( www.biomedcentral.com/1471-2202/9/22 ), the ...
... left patients almost 5 times more likely to become ... Black Americans are more likely than other racial groups ... or increased pressure in the brain, according to a ... Medicine in Atlanta reviewed the medical records of all ...
... - Two abstracts underscoring the importance of testing for ... at this week,s Society of Gynecologic Oncologists 39th Annual ... of Texas M. D. Anderson Cancer Center. ... led by M.D. Anderson found advanced- stage ovarian cancer ...
... For her legislative,accomplishments on mental health issues, Colorado ... State Legislator of the Year Award of the,American ... with the award in recognition of her advocacy ... D.C., "Senator Keller has been a champion ...
Cached Medicine News:Health News:How do infections and toxins launch a cell's self-destruct and alarm system? 2Health News:How do infections and toxins launch a cell's self-destruct and alarm system? 3Health News:Gulf War Illness Strongly Linked to Chemical Exposure 2Health News:Gulf War Illness Strongly Linked to Chemical Exposure 3Health News:Injection of human umbilical cord blood helps the aging brain 2Health News:Brain Disease Causes More Vision Loss in Blacks 2Health News:Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment 2Health News:Colorado State Senator Keller Recognized for Advocacy Work on Mental Health Issues 2
... gel drying system, 100-120 V, includes Model 583 ... Model 583 gel dryer is a vacuum-based gel ... 45 cm with variable temperature control and three ... water-based pump used for pulling vacuum on gel ...
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... is the most versatile power supply in ... 1000 volts or 1250 milliamps or 325 ... other 1000 volt power supply is capable ... protein gels or small focusing gels and ...
... DNA sequencing, Thermo Series 90 high voltage ... applications. These power supplies can operate ... power operating modes, with automatic crossover. To ... the Series 90 power supplies, four sets ...
Medicine Products: